A device developed by MGH investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology
A device developed by Massachusetts General Hospital investigators may bring rapid, accurate molecular diagnosis of tumors and other diseases to locations lacking the latest medical technology. In their report appearing in PNAS Early Edition, the researchers describe a smartphone-based device that uses the kind of technology used to make holograms to collect detailed microscopic images for digital analysis of the molecular composition of cells and tissues.
“The global burden of cancer, limited access to prompt pathology services in many regions and emerging cell profiling technologies increase the need for low-cost, portable and rapid diagnostic approaches that can be delivered at the point of care,” says Cesar Castro, MD, of the MGH Cancer Center and Center for Systems Biology, co-lead author of the report. “The emerging genomic and biological data for various cancers, which can be essential to choosing the most appropriate therapy, supports the need for molecular profiling strategies that are more accessible to providers, clinical investigators and patients; and we believe the platform we have developed provides essential features at an extraordinary low cost.”
The device the team has developed – called the D3 (digital diffraction diagnosis) system – features an imaging module with a battery-powered LED light clipped onto a standard smartphone that records high-resolution imaging data with its camera. With a much greater field of view than traditional microscopy, the D3 system is capable of recording data on more than 100,000 cells from a blood or tissue sample in a single image. The data can then be transmitted for analysis to a remote graphic-processing server via a secure, encrypted cloud service, and the results rapidly returned to the point of care.
For molecular analysis of tumors, a sample of blood or tissue is labeled with microbeads that bind to known cancer-related molecules and loaded into the D3 imaging module. After the image is recorded and data transmitted to the server, the presence of specific molecules is detected by analyzing the diffraction patterns generated by the microbeads. The use of variously sized or coated beads may offer unique diffraction signatures to facilitate detection. A numerical algorithm developed by the research team for the D3 platform is capable of distinguishing cells from beads and of analyzing as much as 10 MB of data in less than nine hundredths of a second.
A pilot test of the system with cancer cell lines detected the presence of tumor proteins with an accuracy matching that of the current gold standard for molecular profiling, and the larger field of view enabled simultaneous analysis of more than 100,000 cells at a time. The investigators then conducted analysis of cervical biopsy samples from 25 women with abnormal PAP smears – samples collected along with those used for clinical diagnosis – using microbeads tagged with antibodies against three published markers of cervical cancer. Based on the number of antibody-tagged microbeads binding to cells, D3 analysis promptly and reliably categorized biopsy samples as high-risk, low-risk or benign, with results matching those of conventional pathologic analysis.
Read more: Smartphone-based device could provide rapid, low-cost molecular tumor diagnosis
The Latest on: Molecular tumor diagnosis
[google_news title=”” keyword=”Molecular tumor diagnosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Molecular tumor diagnosis
- AI Tool Predicts Responses to Cancer Therapy Using Info from Each Tumor Cellon April 19, 2024 at 1:40 pm
Study showcases the power of machine learning to predict therapy outcomes using rich information from single-cell omics ...
- Next-generation breast cancer testing launchedon April 19, 2024 at 7:10 am
Detoxicare Molecular Diagnostics Laboratory forged a partnership deal with a global patient-focused biopharmaceutical company AstraZeneca for next-generation sequencing for breast cancer. The ...
- PathGen Secures Funding to Make Cancer Testing Affordableon April 19, 2024 at 2:03 am
Indonesia's health startup, PathGen Diagnostik Teknologi, secures funding from East Ventures and Royal Group for its molecular testing.
- New Diagnostic Techniques for Breast Cancer Detectionon April 15, 2024 at 5:00 pm
It also aids in cancer management by assessing response ... Newer diagnostic techniques such as sestamibi scans, optical imaging and molecular diagnostic techniques look promising, but need ...
- UPDATE: Predicine Introduces PredicineCARE™ NGS Kit for Tumor Profilingon April 11, 2024 at 8:41 pm
HAYWARD, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced the release of its innovative PredicineCARE™ NGS Kit. This offering presents a ...
- Expanding research and clinical options for children with canceron April 8, 2024 at 9:06 am
In this interview, Dr. Church, the Molecular and Pediatric Pathologist at Boston Children's Hospital, talks to NewsMedical about their work in pediatric oncology, and the need to expand research and ...
- Molecular subtypes of advanced kidney cancer matter for treatment responseon April 5, 2024 at 8:33 am
A combination of immunotherapy and targeted therapies show promise in managing metastatic renal cell carcinoma (RCC), the most common form of kidney cancer that makes up 90% of all cases. However, ...
- Microbial signature of colorectal cancer-associated mutations identifiedon April 4, 2024 at 6:00 am
For about 40% of people diagnosed with colorectal cancer (CRC), the tumor carries a mutation in a gene called KRAS. Many of those mutations have been linked to shorter survival and more aggressive ...
- Molecular imaging technique could improve breast cancer screeningon March 27, 2024 at 5:01 pm
is a novel molecular breast imaging technique that could potentially replace or supplement mammography. With this in mind, researchers in Canada have compared the performance of PEM and breast MRI in ...
- USA Health researchers identify potential biomarker for early pancreatic cancer diagnosison March 27, 2024 at 4:04 pm
Their research was published in Molecular Cancer Research ... of patients to establish TOMM22 as a useful biomarker for early diagnosis and prognosis,” he added. The release noted that this ...
via Bing News